Patients across the UK taking widely prescribed blood pressure medications such as Ramipril and Propranolol are being urged to plan ahead as ongoing supply shortages continue to affect pharmacies nationwide. The Department of Health and Social Care (DHSC) has stepped in with temporary measures to ensure that stocks are managed fairly and that patients can still access their essential treatments without unnecessary disruption.
Serious Shortage Protocol for Ramipril Capsules
According to health monitoring platform MediWatch, a "Serious Shortage Protocol is active for Ramipril 1.25mg capsules in the current official data." This protocol, designated SSP087, was issued by the DHSC on April 22 and has been extended beyond May 29, allowing community pharmacies to limit dispensing to a maximum of one month's supply per prescription, even if the prescription normally covers two or three months. Importantly, no prescription charges apply when medication is supplied under this protocol.
The tracking service advises patients to speak directly with their local pharmacist to understand what the active protocol allows before accepting any alternative quantity, strength, or formulation. These official protocols enable high street chemists to supply smaller quantities of medication to prevent stocks from running out completely. Patients are encouraged to check their current prescriptions early so they do not face unexpected delays in receiving their daily treatment.
Alternatives and Safety Recall
MediWatch highlighted that Ramipril 1.25mg and 2.5mg tablets, plus the oral solution, remain available. However, the DHSC has warned that these alternatives cannot meet increased demand if all capsule patients switch to these forms. The platform advises: "If you take 1.25mg capsules, you should contact your pharmacist about tablet alternatives now - before stocks of those run low too."
Adding to the pressure, a Class 2 recall was issued on April 20 for one batch of Ramipril 10mg capsules (manufactured by Crescent Pharma) due to a packaging error - some cartons contained 5mg blister strips instead of 10mg. MediWatch clarified that this is a safety issue, not a supply issue, but it adds further strain to the overall Ramipril supply chain.
Ramipril's Popularity and Impact
Ramipril is an ACE inhibitor, among the most frequently prescribed medications for high blood pressure in the UK. MediWatch reports that "Over 35 million Ramipril items were dispensed in England alone during 2025, making it one of the top 10 prescribed drugs in the country." The platform explains its widespread use: "It belongs to a family of medicines that all work in a similar way, but Ramipril is particularly favoured because it has a long half-life (stays in your body for a while) and can be taken once daily." This popularity makes maintaining a steady national supply particularly vital for patient care.
Propranolol Shortage: Medium Alert
MediWatch also highlighted that another common heart medication, Propranolol, is listed under a 'medium' alert, noting that "Propranolol modified-release (MR) capsules are present in current active official shortage data." However, Propranolol 40mg and 80mg immediate-release (IR) tablets remain obtainable and "can support increased demand."
Propranolol is a beta-blocker commonly prescribed to manage high blood pressure, anxiety, migraine prevention, and essential tremor. The shortage affects only the modified-release (slow-acting) capsules; the immediate-release tablet versions remain fully available. Patients switching from MR to IR formulations may need their GP to adjust their dosing schedule, as MR capsules are typically taken once daily while IR tablets are usually taken two or three times a day.
What Patients Should Do
Patients currently taking Ramipril 1.25mg capsules or Propranolol MR capsules are advised to contact their local pharmacy or GP practice to discuss alternatives and ensure continuity of treatment. Pharmacists can provide guidance on what the Serious Shortage Protocol permits and whether a switch to an alternative formulation is appropriate. Early action is key to avoiding any interruption in medication supply.
